Concepedia

Kim Papp

KP

Statistics

Publications

310

Citations

45.2K

H-Index

101

Active since

1977

Affiliations

Probity Medical Research(Current)

Icahn School of Medicine at Mount Sinai

Oregon Medical Research Center

University of Toronto

Dalhousie University

Kim Papp is an author at Probity Medical Research specializing in psoriatic disease, medicine, and psoriasis therapy.

ORCID

Publications per year

1977–2025

310

Publications

310

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · New England Journal of Medicine · 2014 · 2K citations · Full text

, , +14

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Craig L. Leonardi, Alexa B. Kimball, Kim Papp et al. · The Lancet · 2008 · 1.9K citations

, , +15

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Kim Papp, Richard G. Langley, Mark Lebwohl et al. · The Lancet · 2008 · 1.4K citations

, , +15

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham et al. · The Lancet · 2017 · 1.2K citations · Full text

, , +17

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial

Stephen K. Tyring, Alice B. Gottlieb, Kim Papp et al. · The Lancet · 2005 · 1.1K citations

, , +6

1–5 of 310